Motilium contains domperidone, a peripheral dopamine D2 receptor antagonist that improves gastrointestinal motility. Clinicians prescribe it primarily to relieve short-term nausea and vomiting, lessen early satiety and post-meal bloating, and manage symptoms of delayed gastric emptying such as gastroparesis. By enhancing coordinated gastric contractions and increasing lower esophageal sphincter tone, domperidone helps food leave the stomach more efficiently and can reduce regurgitation and queasiness. It is used as a symptomatic aid while the underlying cause of nausea, vomiting, or dyspepsia is being evaluated.
Domperidone acts mainly in the gut rather than the brain. By blocking D2 receptors in the gastrointestinal tract, it reduces dopamine’s inhibitory effects on motility, promoting antral contractions and facilitating gastric emptying. Compared with centrally acting antiemetics, domperidone has limited penetration into the central nervous system; this reduces the risk of certain neurologic adverse effects but does not eliminate systemic risks, particularly cardiac effects at higher blood concentrations.
Conditions and scenarios in which Motilium may be considered include:
Motilium is not curative, and it is not the best choice for every type of nausea. For example, chemotherapy-induced nausea usually responds better to serotonin (5-HT3) antagonists, and motion sickness is typically treated with antihistamines or anticholinergics. Before starting domperidone, it is important to identify red flag symptoms such as vomiting blood, black stools, severe abdominal pain, unintentional weight loss, or persistent symptoms beyond a few days, as these warrant prompt medical evaluation.
For adults, a commonly used regimen is 10 mg taken up to three times daily, preferably 15–30 minutes before meals to optimize its prokinetic effect. If nighttime symptoms occur, some clinicians add a dose at bedtime. The general maximum recommended daily dose is 30 mg. Use the lowest effective dose for the shortest possible duration; many acute nausea scenarios call for a course of three to seven days. For chronic symptomatic conditions such as gastroparesis, treatment may be limited to several weeks with regular reassessment to determine ongoing need and safety.
Key directions for use:
Special populations and adjustments:
Never change your dose or schedule without medical advice. If symptoms persist despite appropriate dosing for several days, or if they recur shortly after stopping, seek clinical reassessment to check for underlying conditions or alternative therapies.
Domperidone can prolong the QT interval on an electrocardiogram. Prolongation increases the risk of torsades de pointes and other serious ventricular arrhythmias, particularly at higher doses, in people older than 60, in those with electrolyte abnormalities (low potassium or magnesium), structural heart disease, congenital long QT syndrome, bradycardia, or when combined with interacting drugs. If you have a history of fainting, palpitations, unexplained seizures, or family history of sudden cardiac death, inform your clinician before starting Motilium.
Other important precautions:
Because risks are dose-dependent, clinicians often begin with the lowest feasible dose and reassess response quickly. If you have cardiac risk factors, your clinician may recommend a baseline ECG and periodic checks, especially for courses longer than a few days or if you are taking other medications with potential QT effects.
Do not take Motilium (domperidone) if any of the following apply to you:
A clinician should review your medical history, ECG when indicated, and full medication list before prescribing domperidone, especially if you have conditions that can increase the risk of arrhythmias.
Most people tolerate short courses of domperidone, but side effects can occur. Common effects are usually mild and self-limited:
Prolactin-related effects may develop with ongoing use:
Uncommon but potentially serious effects require prompt medical attention:
If you develop warning signs of an arrhythmia (sudden fainting, sudden fast or irregular pulse) or symptoms of an allergic reaction, seek urgent care. Report any persistent or bothersome adverse effects to your clinician; dose reduction or discontinuation may be necessary.
Domperidone is metabolized by CYP3A4. Medicines that inhibit CYP3A4 can elevate domperidone levels and increase the risk of QT prolongation and arrhythmias. Combining domperidone with other QT‑prolonging drugs further amplifies this risk. Provide your clinician and pharmacist with a complete list of prescription drugs, over-the-counter products, and supplements.
Avoid or use extreme caution with the following:
Other interactions to keep in mind:
Take the missed dose when you remember unless it is close to the time for your next dose. If it is nearly time for the next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed dose.
Symptoms of domperidone overdose may include marked drowsiness, agitation, confusion, severe dizziness, palpitations, fainting, or an unusually fast or irregular heartbeat. Overdose can precipitate dangerous cardiac arrhythmias. Call emergency services immediately. Do not attempt to self-treat. Medical teams may provide continuous cardiac monitoring, correct electrolytes, and offer supportive care until the medicine is cleared.
Store Motilium at room temperature, ideally 20–25°C (68–77°F). Keep it away from moisture, heat, and direct light. Store tablets or suspension in the original, tightly closed container. Do not use after the expiration date, and keep all medications out of the reach of children and pets. Do not share prescription medications with others.
In the United States, domperidone is not FDA‑approved for general use. Access is limited to specific, regulated pathways designed to protect patient safety. U.S. patients should not purchase domperidone from unverified websites, foreign pharmacies that do not require clinician oversight, or vendors that claim to ship without a prescription. Such channels carry medical and legal risks and may supply substandard or counterfeit products.
To obtain domperidone legally in the U.S., a licensed physician must determine that potential benefits outweigh risks and may seek access through the FDA’s Expanded Access Investigational New Drug (IND) program for domperidone. Under this program, physicians enroll patients, provide appropriate monitoring (including ECGs when indicated), and coordinate dispensing through authorized pharmacies that comply with federal requirements. This pathway ensures quality, traceability, and safety monitoring.
If you are exploring treatment for gastroparesis or persistent nausea, the safest route is to schedule a medical evaluation. HealthSouth Rehabilitation Hospital of Montgomery can connect you with clinicians who understand domperidone’s benefits and risks and can advise on appropriate alternatives such as dietary measures, glycemic optimization for diabetics, and other antiemetics or prokinetics. If domperidone is considered appropriate, your clinician can discuss whether an FDA-regulated access pathway is feasible for your situation.
Practical steps for U.S. patients considering Motilium:
Buying Motilium online should only occur through licensed, verifiable channels that require clinician oversight. HealthSouth Rehabilitation Hospital of Montgomery can facilitate legitimate, safe access by arranging a medical evaluation and, when appropriate, coordinating care through lawful U.S. programs. Avoid any service that claims you can obtain domperidone without clinician involvement or outside established regulatory frameworks.
Domperidone (Motilium) is not FDA‑approved for general distribution in the United States. Lawful access typically requires a U.S.-licensed physician to oversee care and, when appropriate, to request supply under the FDA’s Expanded Access IND program. There is no legal pathway to obtain domperidone in the U.S. without physician oversight; claims to the contrary should be treated with caution.
HealthSouth Rehabilitation Hospital of Montgomery offers a legal and structured solution for patients who may benefit from domperidone by providing clinical evaluation, risk assessment, and, where appropriate, coordination of access through compliant, physician-supervised pathways. This approach prioritizes safety, product quality, and adherence to all U.S. regulations. Patients should avoid unverified vendors or importation schemes and instead work with licensed clinicians and hospital-affiliated or state-licensed pharmacy channels that verify eligibility and provide appropriate monitoring.
If you believe Motilium might be right for you, contact a qualified healthcare professional or HealthSouth Rehabilitation Hospital of Montgomery to discuss your symptoms, review safer alternatives, and outline the steps required for lawful access where clinically justified.
Motilium contains domperidone, a dopamine D2 receptor antagonist that enhances gastric motility (prokinetic) and helps move food through the stomach faster. It also acts as an antiemetic by blocking dopamine receptors in the gut chemoreceptor trigger zone, reducing nausea and vomiting.
It is used short term for nausea and vomiting, and to relieve symptoms of delayed gastric emptying such as bloating, early fullness, and discomfort in functional dyspepsia or diabetic gastroparesis. It is not a cure for underlying disease and should be used alongside evaluation of the cause of symptoms.
Take it on an empty stomach, usually 15–30 minutes before meals and, if needed, before bedtime. Follow your prescriber’s instructions and use the lowest effective dose for the shortest possible duration.
Dosing varies by country. A common regimen is 10 mg up to three times daily, with many guidelines advising a maximum of 30 mg per day; your doctor may adjust frequency based on your risk factors and response.
Effects typically begin within 30–60 minutes after a dose. Symptom relief often lasts several hours, but timing varies with the individual and whether it’s taken before food.
No. It is intended for short-term use because longer durations and higher doses are linked to heart rhythm problems. If symptoms persist beyond a few days, seek medical review to reassess the cause and treatment plan.
Do not use if you have a known prolonged QT interval, significant heart disease, moderate to severe liver impairment, gastrointestinal bleeding/obstruction/perforation, or a prolactin-secreting tumor. Avoid if you take strong CYP3A4 inhibitors or other QT-prolonging medicines unless a specialist deems it necessary.
Dry mouth, headache, abdominal cramps, and diarrhea are the most reported. It can raise prolactin levels, which may cause breast tenderness, galactorrhea, or menstrual changes.
Warning signs include palpitations, dizziness or fainting (possible arrhythmia), severe abdominal pain, black or bloody stools, or allergic reactions like rash and swelling. Seek urgent care if you experience heart-related symptoms.
Domperidone generally causes minimal central nervous system effects because it poorly crosses the blood–brain barrier. Still, if you feel lightheaded or unwell, avoid driving or operating machinery.
Use in children is restricted in many countries due to cardiac risk. It may be considered only for older children under specialist guidance; never give domperidone to infants without explicit medical advice.
Caution is required because adults over 60 have a higher risk of QT prolongation and serious ventricular arrhythmias. Use only if clearly indicated, at the lowest dose and shortest duration, with careful review of other medicines.
It may ease upper stomach fullness and regurgitation related to delayed gastric emptying but is not a primary acid-suppressing therapy. For reflux, acid-lowering medications and lifestyle changes are usually first-line.
By raising prolactin, it can cause menstrual irregularities, breast swelling, or milk production. These effects typically reverse after stopping the drug.
Skip the missed dose if it’s close to your next dose; do not double up. In overdose or if you develop palpitations, fainting, or severe side effects, seek immediate medical care.
It is not a hangover cure. Alcohol can worsen dehydration and may increase side effects such as lightheadedness; avoid taking domperidone for alcohol-related nausea and focus on hydration and rest.
Data in pregnancy are limited. Use only if the potential benefit outweighs risk and after discussion with your healthcare provider; non-pharmacologic measures or alternative antiemetics are often preferred first.
Domperidone passes into breast milk in small amounts, and while it has been used off-label to enhance lactation, safety concerns—especially maternal cardiac risks—have led many authorities to advise against this practice without specialist oversight. Do not self-medicate to boost milk supply.
Tell your surgical team about all medicines. Domperidone is generally not a first choice for postoperative nausea; it should be avoided if there’s a risk of bowel obstruction or after gastrointestinal surgery unless a clinician specifically recommends it.
People with heart disease or those taking medicines that prolong QT or slow heart rhythm (for example, amiodarone, sotalol, certain calcium-channel blockers) face higher risk of dangerous arrhythmias with domperidone. A clinician should review your ECG and medication list before use.
Avoid in moderate to severe liver impairment. In kidney impairment, your doctor may reduce the dosing frequency; do not use without medical guidance.
Yes. Low potassium or magnesium increases the risk of QT prolongation and serious arrhythmias. Correct electrolyte disturbances before using domperidone.
Avoid strong CYP3A4 inhibitors like clarithromycin, erythromycin, ketoconazole, itraconazole, and ritonavir, as they raise domperidone levels and cardiac risk. Always check interactions with a pharmacist or doctor.
Both improve gastric emptying. Metoclopramide is often preferred for diabetic gastroparesis due to stronger evidence and approval in many countries, but it has more central nervous system side effects; domperidone may be considered when metoclopramide is not tolerated, with cardiac precautions.
Domperidone causes fewer extrapyramidal (movement) side effects and less sedation because it barely crosses into the brain. However, domperidone carries a higher risk of QT prolongation and ventricular arrhythmias, especially at higher doses or with interacting drugs.
Ondansetron (a 5‑HT3 antagonist) is first-line for many causes of acute nausea and vomiting, including postoperative and chemotherapy-induced nausea, and does not speed up gastric emptying. Domperidone may be considered for nausea linked to slow stomach motility; both can affect QT, so avoid combining without advice.
Prochlorperazine is useful for vertigo-related and migraine-associated nausea but has higher risks of sedation, hypotension, and extrapyramidal effects. Domperidone is better tolerated neurologically but has cardiac cautions; choice depends on the cause of nausea and individual risk factors.
Antihistamines like promethazine or cyclizine work better for motion sickness because they target vestibular pathways. Domperidone is not a first-line option for travel-related nausea.
Erythromycin stimulates motilin receptors and can rapidly enhance gastric emptying, but tachyphylaxis develops and it has significant interaction and QT risks. Domperidone has a different mechanism and may be better tolerated short term, yet also carries QT concerns; selection is individualized.
Both are prokinetics for functional dyspepsia; itopride also inhibits acetylcholinesterase and generally has minimal QT effect in studies. Availability varies by region; comparative efficacy is similar, so side-effect profile and access guide choice.
Levosulpiride (a benzamide) has prokinetic and antidepressant/antipsychotic properties, with more central side effects like akathisia and sedation, and it elevates prolactin. Domperidone has fewer CNS effects but more cardiac caution; monitoring needs differ.
Cisapride was withdrawn or restricted in many countries due to serious arrhythmias. Mosapride and prucalopride are 5‑HT4 agonists; prucalopride is used mainly for chronic constipation and is not an antiemetic. Domperidone targets nausea and motility, but cardiac safety remains a key differentiator.
Antihistamines are effective for vestibular nausea and motion sickness but cause sedation and anticholinergic effects. Domperidone is preferred when nausea relates to delayed gastric emptying rather than inner-ear triggers.
Ginger, acupressure, hydration, and dietary adjustments can help mild nausea and have favorable safety profiles. For persistent or severe symptoms, pharmacologic options like domperidone may be considered with medical oversight given its interaction and cardiac risks.
Low-dose haloperidol can treat refractory nausea but has higher risks of extrapyramidal effects and QT prolongation. Domperidone avoids many CNS effects but still requires QT risk assessment; both should be used cautiously with ECG monitoring in high-risk patients.
In dyspepsia with reflux or acid-related symptoms, a PPI addresses acid while domperidone can help motility-related fullness. Combinations should be short term and tailored, ensuring no interacting drugs increase domperidone levels.